These data demonstrated for different tumor entities that pharmacological intervention with rivaroxaban recapitulated the improved antigen presentation and T cell priming capacity of APCs delineated with myeloid FXa-PAR2 signaling–deficient mice and enhanced the main principles of clinically approved check point inhibitor therapy. This evidence concerns the gene F2RL1 and neoplasm.